Biohaven Pharmaceutical (BHVN) and The Competition Financial Comparison

Biohaven Pharmaceutical (NYSE: BHVN) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Biohaven Pharmaceutical to similar companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, risk and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Biohaven Pharmaceutical and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven Pharmaceutical 0 0 6 0 3.00
Biohaven Pharmaceutical Competitors 678 2564 6847 135 2.63

Biohaven Pharmaceutical currently has a consensus target price of $38.00, suggesting a potential upside of 21.64%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.24%. Given Biohaven Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe Biohaven Pharmaceutical is more favorable than its rivals.

Earnings & Valuation

This table compares Biohaven Pharmaceutical and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Biohaven Pharmaceutical N/A -$63.67 million -5.98
Biohaven Pharmaceutical Competitors $219.38 million -$39.59 million -65.32

Biohaven Pharmaceutical’s rivals have higher revenue and earnings than Biohaven Pharmaceutical. Biohaven Pharmaceutical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.


This table compares Biohaven Pharmaceutical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biohaven Pharmaceutical N/A N/A N/A
Biohaven Pharmaceutical Competitors -4,441.89% -463.63% -40.31%

Institutional and Insider Ownership

47.8% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Biohaven Pharmaceutical beats its rivals on 7 of the 12 factors compared.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with's FREE daily email newsletter.

Leave a Reply